Ken Griffin Galmed Pharmaceuticals Ltd. Transaction History

Citadel Advisors LLC

  • $559 Billion
  • Q4 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
BUY
$0.4 - $0.9 $16,337 - $36,759
40,844 New
40,844 $17,000
Q3 2022

Nov 14, 2022
SELL
$0.35 - $59.37 $14,348 - $2.43 Million
-40,997 Reduced 68.76%
18,628 $6,000

About Galmed Pharmaceuticals Ltd.

GLMD Quotes by TradingView
  • Ticker GLMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,088,400
  • Market Cap $67.7M
  • Description
  • Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or t...
More about GLMD
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email